Clinical Trial News
FDA Approves Expanded Use of MED-EL Cochlear Implant System
The FDA has approved the MED-EL Cochlear Implant System for a broader range of patients, including adults with bilateral moderate to profound sensorineural hearing loss who benefit minimally from hearing aids.
Home-Based Exercise Program Significantly Reduces Knee Pain, Study Finds
A two-year study involving 786 participants with knee pain found that a simple home-based exercise program significantly reduces knee pain and improves physical function. The study highlights the importance of exercise adherence for pain reduction and suggests that social support alone does not improve health outcomes.
Culturally Tailored Interventions Boost Cervical Cancer Screening Among Chinese Women in North America
A randomized controlled trial demonstrates that culturally and linguistically appropriate interventions significantly increase Pap testing rates among Chinese women in North America, highlighting the effectiveness of outreach worker visits and direct mail strategies.
Intensive Chemo Shows Promise in Relapsed Ovarian Cancer
• A new intensive chemotherapy regimen demonstrates high effectiveness in treating women with relapsed ovarian cancer after initial chemotherapy failure.
• The treatment, combining cisplatin and etoposide, achieved an 80% tumor shrinkage rate, with 43% of patients showing complete remission.
• The intensive regimen, involving weekly cisplatin administration, proved more effective than standard therapies, offering new hope for patients with limited options.
• Researchers noted the treatment was well-tolerated, with manageable side effects, and the drugs are readily available for immediate patient benefit.
Early Antithymocyte Globulin Therapy Enhances Survival in Steroid-Resistant Acute GVHD Patients
A study reviewing the treatment of 79 hematopoetic stem cell transplant patients with steroid-resistant acute GVHD using equine antithymocyte globulin (ATG) showed a 32% survival rate at one year. The therapy was particularly effective in patients with skin GVHD and early signs of steroid resistance.
ASCO 2024: Lenvatinib plus Pembrolizumab Shows Superiority Over Sunitinib in Advanced Renal Cell Carcinoma
At the 2024 ASCO Annual Meeting, Dr. Viktor Grünwald presented findings from the CLEAR trial, highlighting the efficacy of lenvatinib plus pembrolizumab over sunitinib in treating advanced clear cell renal cell carcinoma. The combination therapy demonstrated significant improvements in overall survival, prolonged time to tumor progression across various organs, and a lower median tumor burden at disease progression.
Regional Chemotherapy for Liver Metastases of Colorectal Cancer Shows Varied Perfusion Patterns
A study involving 82 patients with liver metastases from colorectal cancer treated with continuous chemotherapy via hepatic artery infusion pumps revealed varied liver perfusion patterns. While 70% of patients showed homogeneous liver perfusion, 24% had distinct inhomogeneities, and 6% exhibited selective perfusion of one hepatic lobe, impacting the response to therapy.
Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver
A study involving 93 patients with colorectal cancer metastatic to the liver treated with hepatic arterial infusion of 5-fluorodeoxyuridine (FUDR) showed significant tumor size reduction and prolonged survival, especially in patients without extrahepatic metastases.
D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial
• A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
• The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
• Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.